Payment overview · 2025
General Payments
$638.58
32 reported records · 15 companies
Healthcare provider profile · identity verified
Ryan Asher
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALBUQUERQUE, NM · NPI 1124435235
Verified facts
What the public records show
CMS Open Payments records show Ryan Asher received $638.58 in general payments during 2025 across 32 reported records.
PFIZER INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.72 | 25.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.50 | 19.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.82 | 8.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.52 | 8.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.77 | 7.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.06 | 4.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.14 | 4.6% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $20.42 | 3.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.02 | 3.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.62 | 2.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.76 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.53 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.43 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.70 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.57 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.58 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.65 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.92 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.38 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.59 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $12.96 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 806 | 185 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 729 | 202 |
| Lisinopril | Lisinopril | 581 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 147 |
| Losartan Potassium | Losartan Potassium | 335 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 102 |
| Gabapentin | Gabapentin | 318 | 91 |
| Omeprazole | Omeprazole | 311 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 37 |
| Trazodone Hcl | Trazodone Hcl | 214 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 211 | 94 |
| Metformin Hcl Er | Metformin Hcl | 207 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 51 |
| Metformin Hcl | Metformin Hcl | 191 | 57 |
| Simvastatin | Simvastatin | 186 | 50 |
| Glipizide Er | Glipizide | 176 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 168 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 65 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 16 |
| Ozempic | Semaglutide | 137 | 27 |
| Finasteride | Finasteride | 136 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 38 |
| Donepezil Hcl | Donepezil Hcl | 132 | 35 |
| Alendronate Sodium | Alendronate Sodium | 127 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 125 | 53 |
| Sertraline Hcl | Sertraline Hcl | 119 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 118 | 35 |
| Baclofen | Baclofen | 117 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 33 |
| Furosemide | Furosemide | 108 | 41 |
| Famotidine | Famotidine | 107 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 29 |
| Atenolol | Atenolol | 105 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 26 |
| Allopurinol | Allopurinol | 98 | 30 |
| Meloxicam | Meloxicam | 97 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 27 |
| Montelukast Sodium | Montelukast Sodium | 95 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 23 |
| Prednisone | Prednisone | 90 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 16 |
| Azithromycin | Azithromycin | 87 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Eliquis | Apixaban | 87 | 26 |
| Potassium Chloride | Potassium Chloride | 84 | 34 |
| Carvedilol | Carvedilol | 83 | 25 |
| Mounjaro | Tirzepatide | 82 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 25 |
| Lorazepam | Lorazepam | 78 | 14 |
| Tramadol Hcl | Tramadol Hcl | 78 | 26 |
| Buspirone Hcl | Buspirone Hcl | 76 | 21 |
| Pregabalin | Pregabalin | 76 | 23 |
| Alprazolam | Alprazolam | 69 | 14 |
| Jardiance | Empagliflozin | 67 | 25 |
| Lovastatin | Lovastatin | 67 | 17 |
| Diazepam | Diazepam | 65 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 19 |
| Ibuprofen | Ibuprofen | 61 | 20 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Acyclovir | Acyclovir | 59 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 16 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 39 |
| Mirtazapine | Mirtazapine | 50 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Fluconazole | Fluconazole | 46 | 22 |
| Spironolactone | Spironolactone | 46 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 15 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 14 |
| Glipizide | Glipizide | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 14 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 16 |
| Calcitriol | Calcitriol | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 22 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Naproxen | Naproxen | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $638.58 · 32 records | PFIZER INC. | ABRYSVO, AUSTEDO XR, COMIRNATY, EVENITY, JARDIANCE, JOURNAVX, KISUNLA, LEQVIO, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error